<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387112</url>
  </required_header>
  <id_info>
    <org_study_id>DZHK VAD Study</org_study_id>
    <secondary_id>VAD Study Germany</secondary_id>
    <nct_id>NCT02387112</nct_id>
  </id_info>
  <brief_title>Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation</brief_title>
  <official_title>Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess whether, in patients who are listed for cardiac
      transplantation in transplantable (T) status, early implantation of a left ventricular assist
      device is superior to the current therapeutic strategy of medical heart failure therapy and
      assist device implantation only after serious deterioration of the patient's condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart transplantation is considered the gold-standard therapy for end-stage systolic heart
      failure but the shortage of donor hearts in Germany and other countries has led to widespread
      use of left ventricular assist devices (LVAD). Even on the transplant list, patients'
      condition often deteriorate due to worsening heart failure so that they need an LVAD as a
      bridge until transplantation. The high mortality (one in five patients on the waiting list
      dies within 1 year) reflects the severity of the disease. In comparison, technical progress
      has reduced the complication rate seen with assist devices and, according to recent data,
      mortality during LVAD support is low. Patient status prior to LVAD implantation is a strong
      indicator for postoperative outcome, i.e. patients in worse condition are more likely to
      develop complications. Thus, the comparison between the standard indication and early LVAD
      implantation (T-status) appears timely and clinically necessary.

      The paucity of donor hearts necessitates the prospective evaluation of alternative treatment
      regimens. The aim of the study is to assess whether, in patients with end-stage heart failure
      awaiting cardiac transplantation, a strategy involving early LVAD implantation is superior to
      a strategy of conservative medical heart failure therapy and assist device implantation only
      after severe deterioration of heart failure.

      The investigators expect to gain insights that will be trail-blazing for the future treatment
      of patients with heart failure on the transplantation waiting list, including aspects of
      their medical care. If the study hypotheses are confirmed, the treatment of these seriously
      ill patients could be, on the one hand, further optimized. On the other hand, positive
      economic effects are highly probable.

      The results will form the basis of future guidelines for the treatment of this group of
      patients.

      Thus the study will also make a contribution to solving the problem of the ever increasing
      number of patients on the waiting list as opposed to the decreasing willingness to donate
      organs for transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Mortality in both groups between listing for cardiac transplantation in T Status and follow-up (5 years at the most, 4 years on average)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Freedom from disabling and non-disabling strokes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Listing for high-urgency (HU) cardiac transplantation</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with de novo right heart failure measured by decreasing right heart ejection fraction, increasing central venous pressure and/or secondary organ failure needing catecholamines and/or right ventricular circulatory support</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events due to device failure</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of device infections requiring antibiotics and/surgical intervention</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients suffering from secondary organ failure</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Time to event of renal and/or hepatic failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36)</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Quality of life questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with heart failure questionnaire (MLHFQ)</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Quality of life questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-mental state examination (MMSE)</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Quality of life questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving a donor heart</measure>
    <time_frame>Randomisation untill transplantation (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum oxygen uptake (VO2 max)</measure>
    <time_frame>Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure survival score</measure>
    <time_frame>Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle heart failure score</measure>
    <time_frame>Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with major bleedings (needing &gt;4 Units of blood) following VAD implantation and major bleedings due to anticoagulation therapy</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Bleeding needing hospitalisation, blood transfusion and/or surgical interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association class (NYHA)</measure>
    <time_frame>Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAD explantation due to myocardial recovery</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
    <description>Time to event</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality-adjusted life year (QALY)</measure>
    <time_frame>Randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6 minutes walking test</measure>
    <time_frame>Measured every 6 months from randomisation untill month 60 (60 months at the most, 48 months on average)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>End Stage Heart Disease</condition>
  <arm_group>
    <arm_group_label>Early VAD implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency VAD implantation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Early VAD implantation</intervention_name>
    <description>Implantation of a left ventricular assist device</description>
    <arm_group_label>Early VAD implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient (male or female) eligible for heart transplantation and accepted in T Status
             (transplantable) on the waiting list

          -  Age 18 to 60 years

          -  Signed informed consent

          -  &gt;30% 1-year mortality with the Seattle Heart Failure Model (SHFM) or at least three of
             the following criteria (a) to (f):

               1. cardiac index (CI) &lt;2.5 l/min/m²

               2. pulmonary capillary wedge pressure &gt;15 mmHg

               3. maximal oxygen uptake (VO2max) ≤10.0 ml/kg/min or ≤12.0 ml/kg/min in patients
                  intolerant of a ß-blocker

               4. ratio of minute ventilation (VE) to carbon dioxide (VCO2) production (VE/VCO2)
                  slope of &gt;35

               5. at least two hospitalizations for heart failure within the previous 12 months

               6. documented increase of brain natriuretic peptide (BNP) or NTproBNP levels despite
                  optimal medical therapy

        Exclusion Criteria

          -  Patient is under age

          -  Patient is older than 60 years

          -  Patient is unable to give consent

          -  Contraindications to assist device implantation (e.g. mechanical aortic valve, aortic
             insufficiency)

          -  Contraindications to anticoagulation

          -  Expected need for a right ventricular assist device/biventricular support expected
             (e.g. due to tricuspid valve insufficiency grade 3+, right ventricular ratio
             short/long axis ≥0.6, ratio of right to left ventricular end-diastolic diameter
             (RVEDD/LVEDD) &gt;0.72, restrictive cardiomyopathy)

          -  Presence of catecholamine support or intra-aortic balloon counterpulsation (IABP)

          -  Overt infections

          -  Fixed pulmonary hypertension (i.e. pulmonary arterial pressure (PAP) &gt;60 mmHg and mean
             transpulmonary gradient (TPG) &gt;15 mmHg or pulmonary vascular resistance (PVR) &gt;6 Wood
             units despite optimal medical treatment)

          -  Renal insufficiency (glomerular filtration rate (GFR) &lt;30ml/min or need for
             hemodialysis or hemofiltration)

          -  Significant coagulopathies

          -  Systemic lupus erythematosus, sarcoid, or amyloidosis that has multisystem involvement
             and is still active

          -  Drug abuse and/or alcohol abuse

          -  Incompliance

          -  Elevated panel reactivity levels of &gt;50 %

          -  Pregnancy or breast feeding in women

          -  Informed consent not given after detailed information received
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volkmar Falk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Heart Institute Berlin Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Knosalla, MD, PhD</last_name>
    <phone>++49 30 4593</phone>
    <phone_ext>2000</phone_ext>
    <email>knosalla@dhzb.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Hübler, MD, MBA</last_name>
    <phone>++49 30 4593</phone>
    <phone_ext>2201</phone_ext>
    <email>shuebler@dhzb.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen - Klinik für Thorax-, Herz- und Gefäßchirurgie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Moza, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen - Klinik für Herz- und Gefäßchirurgie</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Siepe, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rieth, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW - Universitätsklinik der Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michiel Morshuis, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin: Campus Charité Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Stangl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin: Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Leistner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin: Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burkert Pieske, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>German Heart Center Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Knosalla, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen - Herzchirurgische Klinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weyand, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Seidler, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Barten, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Schmitto, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arjang Ruhparwar, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Herz- und Thoraxchirurgie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Doenst, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein - Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assad Haneya, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln - Klinik und Poliklinik für Herz- und Thoraxchirurgie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Parwis Rahmanian, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Garbade, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg Klinik für Herz- und thorakale Gefäßchirurgie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainer G. Mossdorf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzchirurgische Klinik und Poliklinik des Klinikums der Universität München - Campus Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Ströh, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven Martnes, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Herz-, Thorax und herznahe Gefäßchirurgie - Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Schmid, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage heart disease</keyword>
  <keyword>Ventricular assist device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

